Sfc Environmental Technologies Limited IPO

01At a glance

What the company does — design, technology, manufacture and supply, and supervision of installation and commissioning of equipment for wastewater treatment, tertiary treatment for recycling and reuse, and solid-waste treatment plants; it had 639 installations in wastewater treatment at March 2025, and the F&S report it cites credits it with over 80% share of India's sequencing batch reactor technology market (DRHP p.29).

Who pays it — EPC contractors and public bodies building sewage and waste plants; the top ten customers, who include Goa Waste Management Corporation, GVPR Engineers and Vishvaraj Environment, were 61.37% of FY25 revenue (DRHP p.48). Goa Waste Management Corporation is the main solid-waste customer (DRHP p.270).

Why it is raising money — ₹696.70 million for working capital, ₹474.60 million to repay debt of the company and its subsidiary Vasudha Waste Treatment, and the rest for general purposes (DRHP p.30).

How fast it has grown — revenue from ₹5,194 million in FY23 to ₹6,575 million in FY24 and ₹6,979 million in FY25 (DRHP p.32).

The one thing to understand — a profitable niche leader whose cash is increasingly tied up in projects. Operating EBITDA margin was about 30% and the company held net cash, but the cash conversion cycle rose from 105 days in FY23 to 232 days in FY25 and operating cash flow was negative in FY24 (DRHP p.61, DRHP p.170).

02The business, in plain words

A water-technology company designs the treatment process for a sewage or waste plant, makes and supplies the key equipment, and supervises its installation, often as technology partner to the EPC contractor that builds the plant for a city or state.

A city awards a sewage plant contract to an EPC contractor → the contractor adopts SFC's sequencing batch reactor process and orders its equipment → SFC designs, supplies and supervises commissioning → the contractor pays SFC under the supply contract.

Earnings equation: Profit ≈ projects supplied × (price − equipment and engineering cost) + O&M income − overheads. Operating EBITDA margin was 29.73% in FY25 (DRHP p.170).

03Where the money comes from

Source: DRHP p.48, DRHP p.170. At March 2025 the wastewater order book was ₹4,597.53 million and the solid-waste order book ₹1,006.34 million (DRHP p.49).

04The growth record

Source: DRHP p.32, DRHP p.61, DRHP p.170.

05What the growth is made of

Slowing. Revenue grew 26.6% in FY24 and 6.1% in FY25, while the order book fell from ₹7,852 million to ₹5,604 million (our arithmetic, DRHP p.170). Acquisitions of subsidiaries cost ₹151.96 million in FY24 and ₹185.13 million in FY25 (DRHP p.101).

06Earnings quality

Operating cash flow over FY23 to FY25 was ₹842.06 million against profit of ₹3,909.90 million (our arithmetic, DRHP p.32, DRHP p.61). Taxes paid were ₹603.98 million in FY25 (DRHP p.101). The cash conversion cycle lengthened from 105 days in FY23 to 232 days in FY25 (DRHP p.170).

07The balance sheet

Source: DRHP p.32, DRHP p.170.

08What the money is for

Source: DRHP p.30.

09Who is selling

Source: DRHP p.29, DRHP p.30, DRHP p.31. The last row is our arithmetic; it covers Veera Venkata Satyanarayana Yannamani, Jaya Chandrakant Gogri (joint), Jayshree Harit Shah (joint), Hardik Suresh Matalia and Parag Bipinchandra Shah.

10Promoters

The promoters are Sandeep Sudhakar Asolkar, Priya Sandeep Asolkar, Prachiti Sandeep Asolkar and Saketchandrasingh Pratapsingh Dhandoriya, who hold 42.84% fully diluted (DRHP p.29, DRHP p.31). Three tax proceedings involving ₹0.01 million are pending against the promoters (DRHP p.33).

11Who already owns it

Source: DRHP p.31. The last row is our arithmetic.

12What changed just before the IPO

• Order book — down 29% in FY25 (our arithmetic, DRHP p.170).
• Acquisitions — subsidiaries acquired in FY24 and FY25 (DRHP p.101).
• Working capital — cash conversion cycle up to 232 days (DRHP p.170).

13Capacity and expansion

Capacity is engineering teams, supply chains and a subsidiary, Chavare Engineering, that makes control panels and automation systems (DRHP p.270). The proceeds fund working capital (DRHP p.30).

14Market size and industry structure

The F&S report cited in the offer document says India's wastewater-treatment market grew 5.4% a year from FY2020 to FY2025 and projects 9.6% a year to FY2030, with the tertiary-treatment market reaching ₹49.24 billion by FY2030 (DRHP p.29). Those projections are F&S's, and newboard has not tested them.

15Competitive position

What the document claims, and what it rests on:

• Over 80% share of sequencing batch reactor technology in India, citing F&S (DRHP p.29).
• High margins — operating EBITDA margin about three times the listed peers' (DRHP p.171).

Against that: customer concentration, no long-term contracts with most customers, slower order intake, and longer cash cycles (DRHP p.48, DRHP p.170).

16Peers the company named

Source: DRHP p.168, DRHP p.171.

No P/E is possible for the company until a price band is set.

17Risks, in plain words

• Customers. Ten customers were 61% of FY25 revenue (DRHP p.48).
• Order book. Down to 0.8 times revenue (DRHP p.170).
• Cash cycle. 232 days in FY25 (DRHP p.170).
• Technology. New technologies could displace its processes (DRHP p.48).
• Subsidiary claims. ₹590.09 million of proceedings against a subsidiary (DRHP p.33).

18Litigation and regulatory matters

Source: DRHP p.33.

19Related-party transactions

Not read in detail for this study.

20What the offer document does not say

In the sections read for this study, the document does not give:

• What the ₹590.09 million claim against a subsidiary concerns, in the pages read.
• Why the order book fell in FY25, in the pages read.
• Which subsidiaries were acquired, and from whom, in the pages read.
• How revenue splits between wastewater and solid waste, in the pages read.
• The price band, lot size or issue dates, which is normal at DRHP stage.

21Five questions for management

1. Why did the order book fall 29% in FY25?
2. What lengthened the cash conversion cycle to 232 days?
3. What is the ₹590 million claim against a subsidiary?
4. How secure is the sequencing batch reactor share as competitors enter?
5. Why are so many shareholders other than the promoters selling now?

1Sources and cited facts

This study was read from 1 document the company filed. The 23 figures it cites are listed under the document each came from, with the page and the sentence as printed.